Yarrow Bioscience, Inc. (YARW)
Yarrow Bioscience is a New Haven biopharmaceutical company developing drugs for inflammatory and immune conditions. It last closed at $14.03 on Nov 17, up 0.68% on the day. The average 12-month price target from 2 analysts is $50.00 (+256.5% from the last close), with a high of $60.00 and a low of $40.00.
Key Stats
Last 12 monthsNot reported for this period.
From YARW's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on YARW in the past 90 days. The average target is $50.00, with a high of $60.00 and a low of $40.00, compared with the last close of $14.03.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Jefferies | Initiated | Buy | $40 |
| Nov 6 | Guggenheim | Initiated | Buy | $60 |
| Aug 3 | BTIG | Initiated | Buy | $58 |
Technical Analysis
The stock is 26% below its 20 day and 52% below its 50 day average. It is 114% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $13.40, and the nearest resistance the Pivot at $14.15.
| RSI (14) | 36.67 | Weak, oversold below 30 | Neutral |
| MACD | -1.70 | Above its signal line | Bullish |
| Stochastic | 35.6 | Middle of its range | Neutral |
| ADX (14) | 39.7 | Trending down | |
| Williams %R | -80.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -137.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −23.6% | Change over 10 sessions | Bearish |
| ATR (14) | $2.47 | Typical daily range, 17.6% of price |
| RSI (14) | 34.18 | Weak, oversold below 30 | Neutral |
| MACD | -4.36 | Below its signal line | Bearish |
| Stochastic | 11.2 | Near the bottom of its range | Oversold |
| ADX (14) | 32.6 | Trending down | |
| Williams %R | -94.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -111.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −48.1% | Change over 10 sessions | Bearish |
| ATR (14) | $5.51 | Typical daily range, 39.3% of price |
What happened before
See how YARW did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How YARW has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in YARW in the last 90 days.
YARW Institutional Ownership
Full report →- ▲48 buying vs 0 selling
- ●Shares held by funds +0.0%
- ●Funds holding +49
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 49 | – | – |
| In funds' top 10 | 1 | – | – |
| Held by funds | – | – | – |
| New / increased | 48 / 0 | – | – |
| Reduced / sold out | 0 / 0 | – | – |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether YARW is in one of them and how their past YARW trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered YARW in an article yet. Here's the latest on the wider market.
About Yarrow Bioscience
Yarrow Bioscience is a biopharmaceutical company based in New Haven, Connecticut, that develops treatments for inflammatory and immune conditions. Its work centers on BET inhibitors, a class of small molecule drugs that aim to calm overactive inflammatory signaling in the body. Its candidates are still in clinical testing and have not been approved for sale. The company's planned focus is on Graves disease and Thyroid Eye Disease, with patients and their treating doctors as the intended users of any approved treatment.
- Headquarters
- New Haven, CT


